Ingenol mebutate as topical treatment for actinic keratosis based on a prospective, non-interventional, multicentre study of real-life clinical practice in Germany: efficacy and quality of life

2019 ◽  
Vol 29 (4) ◽  
pp. 401-408
Author(s):  
Thomas L. Diepgen ◽  
Christoph Eicke ◽  
Mike Bastian
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Multicentre Study ◽  
Actinic Keratosis ◽  
Topical Treatment ◽  
Real Life ◽  
Ingenol Mebutate

Quality of Life and Side Effects in Patients with Actinic Keratosis Treated With Ingenol Mebutate: A Pilot Study

2015 ◽  
Vol 106 (8) ◽  
pp. 644-650 ◽  
Author(s):  
E. Jubert-Esteve ◽  
L.J. del Pozo-Hernando ◽  
N. Izquierdo-Herce ◽  
A. Bauzá-Alonso ◽  
A. Martín-Santiago ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Side Effects ◽  
Actinic Keratosis ◽  
Ingenol Mebutate

Quality of Life and Side Effects in Patients with Actinic Keratosis Treated With Ingenol Mebutate: A Pilot Study

2015 ◽  
Vol 106 (8) ◽  
pp. 644-650 ◽  
Author(s):  
E. Jubert-Esteve ◽  
L.J. del Pozo-Hernando ◽  
N. Izquierdo-Herce ◽  
A. Bauzá-Alonso ◽  
A. Martín-Santiago ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Side Effects ◽  
Actinic Keratosis ◽  
Ingenol Mebutate

Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes

2015 ◽  
Vol 72 (5) ◽  
pp. 816-821 ◽  
Author(s):  
Matthias Augustin ◽  
John H. Tu ◽  
Kim Mark Knudsen ◽  
Sandra Erntoft ◽  
Thomas Larsson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Outcomes ◽  
Actinic Keratosis ◽  
Treatment Satisfaction ◽  
Ingenol Mebutate

scholarly journals Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France

2020 ◽  
Vol 44 (1) ◽  
pp. 36-49
Author(s):  
Romaric Loffroy ◽  
◽  
Maxime Ronot ◽  
Michel Greget ◽  
Antoine Bouvier ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Interim Analysis ◽  
Real Life ◽  
Life Outcomes ◽  
Liver Tumours ◽  
Eortc Qlq C30 ◽  
Eortc Qlq ◽  
Randomised Controlled

Abstract Purpose Radioembolization has emerged as a treatment modality for patients with primary and secondary liver tumours. This observational study CIRT-FR (CIRSE Registry for SIR-Spheres Therapy in France) aims to evaluate real-life clinical practice on all patients treated with transarterial radioembolization (TARE) using SIR-Spheres yttrium-90 resin microspheres in France. In this interim analysis, safety and quality of life data are presented. Final results of the study, including secondary effectiveness outcomes, will be published later. Overall, CIRT-FR is aiming to support French authorities in the decision making on reimbursement considerations for this treatment. Methods Data on patients enrolled in CIRT-FR from August 2017 to October 2019 were analysed. The interim analysis describes clinical practice, baseline characteristics, safety (adverse events according to CTCTAE 4.03) and quality of life (according to EORTC QLQ C30 and HCC module) aspects after TARE. Results This cohort included 200 patients with hepatocellular carcinoma (114), metastatic colorectal cancer (mCRC; 38) and intrahepatic cholangiocarcinoma (33) amongst others (15). TARE was predominantly assigned as a palliative treatment (79%). 12% of patients experienced at least one adverse event in the 30 days following treatment; 30-day mortality was 1%. Overall, global health score remained stable between baseline (66.7%), treatment (62.5%) and the first follow-up (66.7%). Conclusion This interim analysis demonstrates that data regarding safety and quality of life generated by randomised-controlled trials is reflected when assessing the real-world application of TARE. Trial Registration Clinical Trials.gov NCT03256994.

Sign in / Sign up

Export Citation Format

Share Document